BiotechTube

Lumiracoxib

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Musculoskeletal Pain

Conditions

Musculoskeletal Pain

Trial Timeline

Nov 1, 2004 → —

NCT ID
NCT00170898

About Lumiracoxib

Lumiracoxib is a approved stage product being developed by Novartis for Musculoskeletal Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00170898. Target conditions include Musculoskeletal Pain.

What happened to similar drugs?

0 of 1 similar drugs in Musculoskeletal Pain were approved

Approved (0) Terminated (0) Active (1)
🔄Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (14)

NCT IDPhaseStatus
NCT00419796ApprovedCompleted
NCT00333567ApprovedCompleted
NCT00350155ApprovedCompleted
NCT00348491ApprovedCompleted
NCT00267176ApprovedCompleted
NCT00170781ApprovedCompleted
NCT00170898ApprovedCompleted
NCT00170872Phase 3Completed
NCT00145301Phase 3Completed
NCT00475800Phase 3Completed
NCT00476034Phase 3Completed
NCT00366938Phase 3Completed
NCT00367315Phase 3Completed
NCT00267215Phase 3Completed

Competing Products

4 competing products in Musculoskeletal Pain

See all competitors
ProductCompanyStageHype Score
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
No interventionJohnson & JohnsonPre-clinical
26
ACE-083MerckPhase 1
29
Nerve Growth FactorLundbeckPre-clinical
15